tiprankstipranks
Advertisement
Advertisement

EVMN Stock Latest News

Evommune price target lowered to $29 from $30 at RBC Capital
The FlyEvommune price target lowered to $29 from $30 at RBC Capital
9d ago
EVMN
Evommune reports Q2 EPS (89c), consensus (67c)
PremiumThe Fly
Evommune reports Q2 EPS (89c), consensus (67c)
10d ago
EVMN
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
PremiumCompany Announcements
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
17d ago
8K
EVMN
Evommune initiates Phase 2b trial of EVO756
PremiumThe Fly
Evommune initiates Phase 2b trial of EVO756
17d ago
EVMN
Evommune participates in a conference call with Cantor
PremiumThe Fly
Evommune participates in a conference call with Cantor
18d ago
EVMN
Clear Street sees attractive point into Evommune after selloff
PremiumThe FlyClear Street sees attractive point into Evommune after selloff
1M ago
EVMN
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
Premium
Company Announcements
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
2M ago
EVMN
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
Premium
Company Announcements
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
2M ago
EVMN
Septerna price target lowered to $45 from $52 at Guggenheim
PremiumThe Fly
Septerna price target lowered to $45 from $52 at Guggenheim
2M ago
EVMN
SEPN
Evommune price target lowered to $26 from $55 at Morgan Stanley
PremiumThe Fly
Evommune price target lowered to $26 from $55 at Morgan Stanley
2M ago
EVMN
Evommune downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Evommune downgraded to Neutral from Buy at H.C. Wainwright
2M ago
EVMN
Evommune price target lowered to $28 from $53 at Clear Street
PremiumThe Fly
Evommune price target lowered to $28 from $53 at Clear Street
2M ago
EVMN
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
PremiumThe FlyMidday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
2M ago
VZ
CRM
Evommune downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Evommune downgraded to Market Perform from Outperform at William Blair
2M ago
EVMN
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
Premium
Company Announcements
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
2M ago
8K
EVMN
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
PremiumThe Fly
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
2M ago
EVMN
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
PremiumThe Fly
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
2M ago
ABBV
APGE
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
PremiumThe Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
2M ago
ABBV
APGE
Evommune Stockholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
Evommune Stockholders Reelect Directors and Ratify Auditor
2M ago
8K
EVMN
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
PremiumRatingsEvommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
3M ago
EVMN
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
Premium
Ratings
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
3M ago
EVMN
Evommune price target raised to $55 from $54 at Morgan Stanley
Premium
The Fly
Evommune price target raised to $55 from $54 at Morgan Stanley
3M ago
EVMN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >